Invivoscribe Claims Win in FLT3 Patent Case | GenomeWeb

NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said that a German court has ruled in its favor in a patent dispute over FLT3 testing technology.

The San Diego-based firm said that the German District court in Munich found MLL Muenchner Leukaemielabor GmbH Laboratories guilty of infringing a patent held by Takara Bio and licensed exclusively to Invivoscribe. It also noted that the court declined to stay enforcement of its decision.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.